New insulins in the treatment of diabetes mellitus

Bailliere's Best Practice and Research in Clinical Gastroenterology

Volumn 16, Issue 3, 2002, Pages 475-492

  Lindholm, Anders ^a  

^a Novo Nordisk Ltd   (United Kingdom)

Author keywords

Diabetes mellitus; Insulin analogues; Insulin aspart; Insulin detemir; Insulin glargine; Insulin lispro; Insulin treatment

Indexed keywords

BIPHASIC INSULIN; HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; ANTIDIABETIC AGENT; CARRIER PROTEIN; DRUG DERIVATIVE; GLARGINE; INSULIN, ASP(B28)-;

DIABETES MELLITUS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG STRUCTURE; DRUG USE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN TREATMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; REVIEW; AREA UNDER THE CURVE; BLOOD GLUCOSE MONITORING; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; INCIDENCE; MITOGENICITY; POSTPRANDIAL STATE; RISK FACTOR;

CARRIER PROTEINS; DIABETES MELLITUS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN;

EID: 0036597493     PISSN: 15216918     EISSN: None     Source Type: Journal    
DOI: 10.1053/bega.2002.0321     Document Type: Article

References (94)

1. Pyke D A Preamble: the history of diabetes In Alberti K (Ed.) GMM International Textbook of Diabetes Mellitus 1997 1-6 John Wiley Chchester (UK)
2. Owens D R Zinman B Bolli G B Insulins today and beyond Lancet 358 2001 739-746
3. DCCT Research Group. The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial Diabetes 45 1996 1289-1298
4. UKPDS33. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes Lancet 352 1998 837-853
5. Stratton I M Adler A I Neil H A et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study British Medical Journal 321 2000 405-412
6. DCCT Research Group. Hypoglycemia in the Diabetes Control and Complications Trial Diabetes 46 1997 271-286
7. Hanefeld M Fischer S Julius U et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up Diabetologia 39 1996 1577-1583
8. Tominaga M Igarishi K Eguchi H et al. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose Diabetes Care 22 1999 920-924
9. DECODE study group, European Diabetes Epidemiology group. Glucose tolerance and mortality: Comparison of WHO and American Diabetes Association diagnostic criteria Lancet 354 1999 617-621
10. Brundin T Splanchnic and extrasplanchnic extraction of insulin following oral and intravenous glucose loads Clinical Science 97 1999 429-436
11. Tura A Ludvik B Nolan J J et al. Insulin and C-peptide secretion and kinetics in humans: direct and model-based measurements during OGTT American Journal of Physiology, Endocrinology and Metabolism 281 2001 E966-E974
12. Kang S Brange J Birch A et al. Subcutaneous insulin absorption explained by insulin's physicochemical properties. Evidence from absorption studies of soluble human insulin and insulin analogues in humans Diabetes Care 14 1991 942-948
13. Hildebrandt P Sejrsen P Nielsen S L et al. Diffusion and polymerisation determine the insulin absorption from subcutaneous tissue in diabetic patients Scandinavian Journal of Clinical and Laboratory Investigation 45 1985 685-690
14. Lauritzen T Faber O K Binder L Variation in insulin absorption and blood glucose concentrations Diabetologia 17 1979 291-295
15. Hildebrandt P Subcutaneous absorption of insulin in insulin-dependent diabetic patients Danish Medical Bulletin 38 1991 337-346
16. Polonsky K S Sturis J Bell G J Seminars in medicine of the Beth Israel Hospital, Boston. Non-insulin dependent diabetes mellitus - a genetically programmed failure of the beta cell to compensate for insulin resistance New England Journal of Medicine 334 1996 777-783
17. Overmann H Heinemann L Injection-meal interval: recommendations of diabetologists and how patients handle it Diabetes Research and Clinical Practice 43 1999 137-142
18. Heise T Heinemann L Rapid and long-acting analogues as an approach to improve insulin therapy: an evidence-based medicine assessment Current Pharmaceutical Design 7 2001 1303-1325
19. Kurtzhals P Schaffer L Sorensen A et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use Diabetes 49 2000 999-1005
20. Hansen B F Danielsen G M Drejer K et al. Sustained signalling from the insulin receptor after stimulation with insulin analogues exhibiting increased mitogenic potency Biochemical Journal 315 1996 271-279
21. Jørgensen L N Dideriksen L H Drejer K Carcinogenic effect of human insulin analogue B10Asp in female rats Diabetologia 35 1992 A3
22. Brange J Ribel U Hansen J F et al. Monomeric insulins obtained by protein engineering and their medical implications Nature 333 1988 679-682
23. Howey D C Bowsher R R Brunelle R L Woodworth J R ([Lys(B28), Pro(B29)])-human insulin. A rapidly absorbed analog of human insulin Diabetes 43 1994 396-402
24. Woodworth J Howey D Bowsher R [Lys(B28), Pro(B29)]-human insulin (K): Dose-ranging vs. Humulin R (H) Diabetes 42 1993 (supplement 1) 54A
25. Ter Braak E W Woodworth J R Bianchi R et al. Injection site effects on the pharmacokinetics of and glucodynamics of insulin lispro and regular insulin Diabetes Care 19 1996 1437-1440
26. Heinemann L Heise T Wahl L C et al. Prandial glycaemia after a carbohydrate-rich meal in type I diabetic patients: using the rapid acting insulin analogue [Lys(B28, Pro(B29)] human insulin Diabetic Medicine 13 1996 625-629
27. Pampanelli S Torlone E Ialli C et al. Improved postprandial metabolic control after subcutaneous injection of a short-acting insulin analogue in IDDM of short duration with residual pancreatic beta-cell function Diabetes Care 18 1995 1452-1459
28. Anderson J H Brunelle R L Keohane P et al. Mealtime treatment with insulin analogue improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus Archives of Internal Medicine 157 1997 1249-1255
29. Anderson J H Jr Brunelle R L Koivisto V A et al.Improved mealtime treatment of diabetes mellitus using an insulin analogue Clinical Therapeutics 19 1997 62-72
30. Holleman F Schmitt H Rottiers R et al. Reduced frequency of severe hypoglycaemia and coma in well-controlled IDDM patients treated with insulin lispro Diabetes Care 20 1997 1827-1832
31. Ahmed A B Home P D Optimal provision of daytime NPH insulin in patients using the insulin analog lispro Diabetes Care 21 1998 1707-1713
32. Lalli C Ciofetta M Del Sindaco P et al. Long-term intensive treatment of type 1 diabetes with the short-acting insulin analogue lispro in variable combination with NPH insulin at mealtime Diabetes Care 22 1999 468-477
33. Gale E A A randomized, controlled trial comparing insulin lispro with human soluble insulin in patients with Type 1 diabetes on intensified insulin therapy Diabetic Medicine. 17 2000 209-214
34. Ciofetta M Lalli C Del Sindaco P et al. Contribution of postprandial versus interprandial blood glucose to HbA1c in type 1 diabetes on physiologic intesiove therapy with lispro insulin at mealtime Diabetes Care 22 1999 795-800
35. Chatterjee S Gallen I W Sandler L 2-year prospective audit of the effect of the introduction of insulin lispro in patients with specific clinical indications Diabetes Care 22 1999 1226-1227
36. Del Sindaco P Ciofetta M Lalli C et al. Use of the short-acting insulin analogue lispro in intensive treatment of type 1 diabetes mellitus: importance of appropriate replacement of basal insulin and time-interval injection-meal Diabetic Medicine 15 1998 592-600
37. Heller S R Amiel S A Mansell P Effect of fast-acting insulin analog lispro on the risk of nocturnal hypoglycaemia during intensified insulin therapy Diabetes Care 22 1999 1607-1611
38. Zinman B Basal insulin replacement and use of rapid-acting insulin analogues in patients with type 1 diabetes Endocrine Practice 6 2000 88-92
39. Tamás G y Marre M Astorga R et al. Glycaemic control in type 1 diabetic patients using optimised insulin aspart or human insulin in a randomised multinational study Diabetes Research and Clinical Practice 54 2001 105-114
40. Jovanovic L Optimization of insulin therapy in patients with gestational diabetes Endocrine Practice 6 2000 98-100
41. Bhattacharyya A Brown S Hughes S Vice P A Insulin lispro and regular insulin in pregnancy QJM - Monthly Journal of the Association of Physicians 94 2001 255-260
42. Aisenpreis U Pfutzner A Giehl M Pharmacokinetics and pharmacodynamics of insulin lispro compared with regular insulin in haemodialysis patients with diabetes mellitus Nephrology, Dialysis, Transplantation 14 1999 (supplement 4) 5-6
43. Bastyr EJ 3rd Johnson M E Trautmann M E et al. Insulin lispro in the treatment of patients with type 2 diabetes mellitus after oral agent failure Clinical Therapeutics 21 1999 1703-1714
44. Zinman B Tildesley H Chiasson J L et al. Insulin lispro in CSII: results of a double-blind crossover study Diabetes 46 1997 440-443
45. Johansson U B Adamson U C Lins P E Wredling R A Improved blood glucose variability, HbA1c insuman Infusat and less insulin requirement in IDDM patients using insulin lispro in CSII Diabetes & Metabolism 26 2000 192-196
46. Garg S K Anderson J H Gerard L A et al. Impact of insulin lispro on HbA1c values in insulin pump users Diabetes Obesity & Metabolism 2 2000 307-311
47. Hanaire-Broutin H Melki V Bessicres-Lacombe S Tauber J P Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens using insulin lispro in type 1 diabetic patients on intensified treatment: a randomised study Diabetes Care 23 2000 1232-1235
48. Lindholm A Jacobsen L V Clinical pharmacokinetics and pharmacodynamics of insulin aspart Clinical Pharmacokinetics 40 2001 641-659
49. Hedman C A Lindstrom T Arnqvist H J Direct comparison of insulin lispro and aspart shows small differences in plasma insulin profiles after subcutaneous injection in Type 1 diabetes Diabetes Care 24 2001 1120-1121
50. Home P D Lindholm A Hylleberg B Round P Improved glycaemic control with insulin aspart: a multicenter randomised double-blind crossover trial in type 1 diabetic patients Diabetes Care 21 1998 1904-1909
51. Mudaliar S R Linberg F A Joyce M et al. Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects Diabetes Care 22 1999 1501-1506
52. Home P D Barriocanal L Lindholm A Comparative Pharmacokinetics and pharmacodynamics of the novel rapid-acting analogue, insulin aspart, in healthy volunteers European Journal of Clinical Pharmacology 55 1999 199-203
53. Lindholm A McEwan J Riis A P Improved glycaemic control with insulin aspart. A randomised double-blind cross-over trial in type 1 diabetes Diabetes Care 22 1999 801-805
54. Mortensen H B Lindholm A Olsen B S Hylleberg B Rapid appearance and onset of action of insulin aspart in paediatric subjects with type 1 diabetes European Journal of Pediatrics 159 2000 483-488
55. Kaku K Matsuda M Urae A Irie S Pharmacokinetics and pharmacodynamics of insulin aspart, a rapid-acting analog of human insulin, in healthy Japanese volunteers Diabetes Research and Clinical Practice 49 2000 119-126
56. Rosenfalck A M Thorsby P Kjems L et al. Improved postprandial glycaemic control with insulin aspart in type 2 diabetic patients treated with insulin Acta Diabetologica 37 2000 41-46
57. Raskin P Guthrie R A Leiter L et al. Use of insulin aspart, a fast-acting analog, as the mealtime insulin in the management of patients with type 1 diabetes Diabetes Care 23 2000 583-588
58. Home P D Lindholm A Riis A et al. Insulin aspart vs. human insulin in the management of long-term blood glucose control in Type 1 diabetes mellitus: a randomised controlled trial Diabetic Medicine 17 2000 762-770
59. Amiel S Home P D Jacobsen J L Lindholm A Insulin aspart safe for long-term treatment Diabetologia 44 2001 (supplement 1) A209
60. Colagiuri S Heller S Vaaler S et al. Insulin aspart reduces the frequency of nocturnal hypoglycaemia in patients with Type 1 diabetes Diabetologia 44 2001 (supplement 1) A210
61. Bode B W Strange P Efficacy, safety and pump compatibility of insulin aspart used in continuous subcutaneous insulin infusion therapy in patients with type 1 diabetes Diabetes Care 24 2001 69-72
62. 2Bode B W Weinstein R Bell D et al. Insulin aspart efficacy and safety compared to buffered regular insulin and insulin lispro for continuous subcutaneous insulin infusion Diabetes 50 2001 (supplement 2) A106
63. Weyer C Heise T Heinemann L Insulin aspart in a 30/70 premixed formulation. Pharmacodynamic properties of a rapid-acting insulin analogue in stable mixture Diabetes Care 20 1997 1612-1614
64. Malone J K Yang H Woodworth J R et al. Humalog Mix25 offers better mealtime glycaemic control in patients with type 1 or type 2 diabetes Diabetes & Metabolism 26 2000 481-487
65. Roach P Strack T Arora V Zhao Z Improved glycaemic control with the use of self-prepared mixtures of insulin lispro and insulin lispro protamine suspension in patients with types 1 and 2 diabetes International Journal of Clinical Practice 55 2001 177-182
66. Jacobsen L V Sogaard B Riis A Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine-retarded insulin aspart European Journal of Clinical Pharmacology 56 2000 399-403
67. Christiansen J S Ejskjaer N Rasmussen M et al. Thrice daily premixed insulin aspart - a new treatment concept in diabetes Diabetic Medicine 18 2001 (supplement 2) 84
68. Home P Insulin glargine: the first clinically useful extended-acting insulin in half a century? Expert Opinion on Investigational Drugs 8 1999 307-314
69. Bolli G B Owens D R Insulin glargine Lancet 356 2000 443-445
70. Hermansen K Madsbad S Perrild H et al. Comparison of the soluble basal insulin analogue insulin detemir with NPH insulin. A randomised open crossover trial in type 1 diabetic subjects on basal-bolus therapy Diabetes Care 24 2001 296-301
71. 125I-labelled insulin glargine (HOE 901) in healthy men. Comparison with NPH insulin and the influence of different subcutaneous injection sites Diabetes Care 23 2000 813-819
72. Jehle P M Micheler C Jehle D R et al. Inadequate suspension of neutral protamine Hagedorn (NPH) in pens Lancet 354 1999 1604-1607
73. Bolli G B Marchi R D Park G D et al. Insulin analogues and their potential in the management of diabetes mellitus Diabetologia 42 1999 1151-1167
74. Raskin P Klaff L Bergenstal R et al. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type I diabetes Diabetes Care 23 2000 1666-1671
75. McKeage K Goa K L Insulin glargine: a review of its therapeutic use as a long-acting agent for the management of type 1 and type 2 diabetes mellitus Drugs 61 2001 1599-1624
76. Heinemann L Linkeschova R Rave K et al. Time-action profile of the long-acting insulin analogue insulin glargine (HOE901) in comparison with those of NPH insulin and placebo Diabetes Care 23 2000 644-649
77. Lepore M Pampanelli S Fanelli C et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analogue glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro Diabetes 29 2000 2142-2148
78. Ratner R E Hirsch I B Neifing J L et al. Less hypoglycemia with insulin glargine in intensive insulin therapy for Type 1 diabetes Diabetes Care 23 2000 639-643
79. Rosenstock J Park G Zimmerman J et al. Basal insulin glargine (HOE 901) versus NPH insulin in patients with Type 1 diabetes on multiple daily insulin regimens Diabetes Care 23 2000 1137-1142
80. Yki-Järvinen H Dressler A Ziemen M Less nocturnal hypoglycaemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in Type 2 diabetes Diabetes Care 23 2000 1130-1136
81. Rosenstock J Schwartz S L Clark C M Jr et al. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin Diabetes Care 24 2001 631-636
82. Pieber T R Eugene-Jolchine I Derobert E et al. Efficacy and safety of HOE 901 versus NPH insulin in patients with Type 1 diabetes Diabetes Care 23 2000 157-162
83. Berger M Safety of insulin glargine Lancet 356 2000 2013-2014
84. Hamilton-Wessler M Ader M Dea M et al. Mechanism of protracted metabolic effects of fatty acid acylated insulin, NN304, in dogs: retention of NN304 by albumin Diabetologia 42 1999 1254-1263
85. Brunner G A Sendhofer G Wutte A Pharmacokinetic and pharmacodynamic properties of long-acting insulin analogue NN304 in comparison to NPH insulin in humans Experimental and Clinical Endocrinology & Diabetes 108 2000 100-105
86. Kurtzhals P Havelund S Jonassen I Markussen J Effect of fatty acids and selected drugs on the albumin binding of a long-acting, acylated insulin analogue Journal of Pharmaceutical Sciences 86 1997 1365-1368
87. Heinemann L Sinha K Weyer C et al. Time-action profile of the soluble, fatty acid acylated, long-acting insulin analogue NN304 Diabetic Medicine 16 1999 322-338
88. Strange P McGill J Mazzeo M Reduced pharmacokinetic variability of a novel, long-acting insulin analog Diabetes 48 1999 A103
89. Selam J L Skeie S Vague P et al. Promising results of 6 months treatment with insulin detemir in type 1 diabetic patients Diabetologia 44 2001 (supplement 1) A15
90. Hamilton-Wessler M Buchanan T A Haahr H et al. Suppression of splanchnic glucose production by insulin detemir in humans reflects change in NEFA availability Diabetologia 44 2001 (supplement 1) A207
91. Hordern V Wright J Umpleby M et al. Stable isotope studies show effect of insulin detemir and NPH on hepatic glucose output and peripheral glucose uptake after subcutaneous administration in healthy subjects Diabetes 50 2001 (supplement 2) A504
92. Home P D Rapid-acting insulin analogues: when randomized clinical trial results do not help Diabetic Medicine 17 2000 (supplement 2) 6-8
93. Hermans M P Nobels F R De Leeuw I Insulin lispro (Humalog®), a novel fast-acting insulin analogue for the treatment of diabetes mellitus: overview of pharmacological and clinical data Acta Clinica Belgica 54-5 1999 233-240
94. Burge M R Schade D Insulins Endocrinology and Metabolism Clinics of North America 26 1997 575-598